What Do Analysts Say About Cymabay Therapeutics, Inc. (CBAY)

HC Wainwright began coverage on shares of CymaBay Therapeutics in a research report on Wednesday, March 28th.

The healthcare sector was on a bumpy ride over the one week as shares of Spectrum surged on positive data from a phase II study, while that of Incyte plunged on the failure of melanoma study. Much of this practice involves discovering the overall trend line of a stock's movement. Cantor Fitzgerald initiated CymaBay Therapeutics, Inc.

CBAY stock opened at $13.50 on Wednesday.

Market Capitalization/Outstanding Shares/Intraday Volume: The company's Market capitalization is $736.18M with the total Outstanding Shares of 56.24M. The default time frame for comparing up periods to down periods is 14, as in 14 trading days.

If you are going to be trading the stock, you want to ensure volume is healthy so you are not stuck in a position. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. The more active the share, higher would be its volume. (CBAY) price hitting a mean target of $20.63 a share, meaning the stock still has potential that could lift the price another 57.6% Also, the recent close suggests the stock is underpriced by 167.38% compared to the most bullish target. Low volume of a security, even if it's rising in price, can indicate a lack of conviction among investors.

There are many marked values in the financial market, which will require a lot of effort, dedication, commitment and motivational spirit of a self to evaluate the recent stock activities efficiently. In a bull trend, buy when prices retrace to the 20-period moving average. Using historical growth rates, for example, may provide an inaccurate PEG ratio if future growth rates are predictable to deviate from historical growth rates. On Wednesday, March 21 the stock of CymaBay Therapeutics, Inc. The stock was sold at an average price of $13.03, for a total transaction of $195,450.00.

More news: Beyonce Unites With Destiny's Child, Jay-Z, & Solange During Coachella Set

Is The Stock Safe to Invest? Typically, active investors are seeking short-term profits. ValuEngine upgraded CymaBay Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. Redmile Group LLC now owns 2,002,265 shares of the biopharmaceutical company's stock worth $18,421,000 after buying an additional 355,165 shares during the last quarter. If we take a long term observation, shares have been trading at a distance of 46.46% from the 200-day moving average. A trend is simply a price that is continuing to move in a certain direction. (2) A downtrend, or bearish trend, means the price is moving lower. However, one should always remember: the trends are more important than the forecasts. The most optimistic analyst sees the stock reaching $35 while the most conventional has $16 target price. Looking deep into the volatility of the stock; it remained 8.87% volatile for the week and 8.28% for the month. This gives investors an idea of how much the security has moved in the previous year and whether it is trading near the top, middle or bottom of the range.

While having a peek at profitability ratios Cymabay Therapeutics (NASDAQ:CBAY) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. A low P/E can indicate either that a company may now be undervalued or that the company is doing exceptionally well relative to its past trends. They issued an outperform rating for the company. Analysts use common formulas and ratios to accomplish this. The company's Relative Strength Index which shows price strength now stands at 54.55. The RSI oscillates between 0 and 100. The amount gives a shareholder an idea of the price action of security and whether he should buy or sell the security.

Infosys Limited is maintained at an average hold rating by 15 stock analysts, and there are at least 4.2% of shares outstanding that are now legally short sold. The company's valuation will be $63.18 million more at $14.58 target. UBS Asset Management Americas Inc. acquired a new stake in CymaBay Therapeutics in the 4th quarter worth about $5,423,000. The stock has performed 11.35% and it registered share value at $13.44 in recent trade transaction.

Weekly, Monthly, Quarterly And Six-Month Performance: Taking a look at the performance of AUY stock, an investor will come to know that the weekly performance for this stock valued at 7.46%, resulting in a performance for the month at 9.92%.

Average True Range (14) for CymaBay Therapeutics, Inc.

Latest News